中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2008年
8期
1054-1056
,共3页
人参皂甙/药理学%肝肿瘤%腹水%新生血管化,病理性%血管内皮生长因子类
人參皂甙/藥理學%肝腫瘤%腹水%新生血管化,病理性%血管內皮生長因子類
인삼조대/약이학%간종류%복수%신생혈관화,병이성%혈관내피생장인자류
Ginsenoside/PD%Liver neoplasms%Ascites%Neovascularization,pathologic%Vascular endothelial growth factors
目的 研究人参皂甙Rg3治疗小鼠恶性腹腔积液的抗血管生成作用.方法 50只雌、雄各半昆明种小鼠随机分为5组:Ⅰ组生理盐水组(0.9%NS);Ⅱ组顺铂组(DDP 0.5 mg/kg);Ⅲ组低剂量人参皂甙Rg3组(LPD 0.3 mg/kg);Ⅳ组中剂量人参皂甙RS3组(MPD 1.0 mg/ks);Ⅴ组高剂量人参皂甙Rg3组(HPD 3.0ms/ks).所有小鼠肝癌H22腹水瘤模型建立后24 h开始分别腹腔注射0.2 ml/只治疗,1次/d,共14 d.治疗结束后24 h,处死各组小鼠,应用酶联免疫吸附法检测腹水及血清中血管内皮生长因子(VEGF),免疫组织化学法计数腹膜瘤结节微血管密度(MVD),电镜观察人参皂甙Rg3中刺量组与生理盐水组腹腔内肿瘤细胞及腹膜瘤结节新生血管的形态学变化.结果 人参皂甙Rg3各剂量组随着用药剂量的加大,小鼠腹水及血清中VEGF值、腹膜瘤结节MVD下降(P＜0.05),且均较生理盐水组、DDP组下降(P＜0.05).电镜观察人参皂甙Rg3中剂量组较生理盐水组腹水中凋亡和坏死瘤细胞居多;腹膜瘤结节微血管基底膜平滑完整.结论 人参皂甙Rg3通过下调荷瘤小鼠体内VEGF,降低微血管的通透性和抑制腹膜微血管形成,从而抑制恶性腹腔积液的形成.这为临床应用提供了实验依据.
目的 研究人參皂甙Rg3治療小鼠噁性腹腔積液的抗血管生成作用.方法 50隻雌、雄各半昆明種小鼠隨機分為5組:Ⅰ組生理鹽水組(0.9%NS);Ⅱ組順鉑組(DDP 0.5 mg/kg);Ⅲ組低劑量人參皂甙Rg3組(LPD 0.3 mg/kg);Ⅳ組中劑量人參皂甙RS3組(MPD 1.0 mg/ks);Ⅴ組高劑量人參皂甙Rg3組(HPD 3.0ms/ks).所有小鼠肝癌H22腹水瘤模型建立後24 h開始分彆腹腔註射0.2 ml/隻治療,1次/d,共14 d.治療結束後24 h,處死各組小鼠,應用酶聯免疫吸附法檢測腹水及血清中血管內皮生長因子(VEGF),免疫組織化學法計數腹膜瘤結節微血管密度(MVD),電鏡觀察人參皂甙Rg3中刺量組與生理鹽水組腹腔內腫瘤細胞及腹膜瘤結節新生血管的形態學變化.結果 人參皂甙Rg3各劑量組隨著用藥劑量的加大,小鼠腹水及血清中VEGF值、腹膜瘤結節MVD下降(P＜0.05),且均較生理鹽水組、DDP組下降(P＜0.05).電鏡觀察人參皂甙Rg3中劑量組較生理鹽水組腹水中凋亡和壞死瘤細胞居多;腹膜瘤結節微血管基底膜平滑完整.結論 人參皂甙Rg3通過下調荷瘤小鼠體內VEGF,降低微血管的通透性和抑製腹膜微血管形成,從而抑製噁性腹腔積液的形成.這為臨床應用提供瞭實驗依據.
목적 연구인삼조대Rg3치료소서악성복강적액적항혈관생성작용.방법 50지자、웅각반곤명충소서수궤분위5조:Ⅰ조생리염수조(0.9%NS);Ⅱ조순박조(DDP 0.5 mg/kg);Ⅲ조저제량인삼조대Rg3조(LPD 0.3 mg/kg);Ⅳ조중제량인삼조대RS3조(MPD 1.0 mg/ks);Ⅴ조고제량인삼조대Rg3조(HPD 3.0ms/ks).소유소서간암H22복수류모형건립후24 h개시분별복강주사0.2 ml/지치료,1차/d,공14 d.치료결속후24 h,처사각조소서,응용매련면역흡부법검측복수급혈청중혈관내피생장인자(VEGF),면역조직화학법계수복막류결절미혈관밀도(MVD),전경관찰인삼조대Rg3중자량조여생리염수조복강내종류세포급복막류결절신생혈관적형태학변화.결과 인삼조대Rg3각제량조수착용약제량적가대,소서복수급혈청중VEGF치、복막류결절MVD하강(P＜0.05),차균교생리염수조、DDP조하강(P＜0.05).전경관찰인삼조대Rg3중제량조교생리염수조복수중조망화배사류세포거다;복막류결절미혈관기저막평활완정.결론 인삼조대Rg3통과하조하류소서체내VEGF,강저미혈관적통투성화억제복막미혈관형성,종이억제악성복강적액적형성.저위림상응용제공료실험의거.
Objective To observe the antiangiogenesis of panaxoside-Rg3 on mice intraperitoneally implanted with ascites tlnnor cells.Methods 25 female and 25 male Kunming mice were random divided into five groups:Group I injected with normal saline (0.9%NS),Group Ⅱ with cisplatin(DDP 0.5mg/kg),Group Ⅲ,with low-dose panaxoside-Rg3(LPD 0.3mg/kg),Group Ⅳ with middle-dose panaxoside-Rg3(MPD 1.0mg/kg),Group Ⅴ with high-dose panaxoside-Rg3(HPD 3.0mg/kg).Experimental ascitic hepatocarcinoma of H22 lines model were successfully established among all groups,and 24 hours later intraperitoneal infusion of 0.2ml medicines was given to each mouse once every day for 14 days.24 hours after the over of the treatment,all mice were executed.Enzyme linked immunosorbent assay(ELISA)method was used to detectt he different VEGF level in the ascites and serum of all groups and expressions of micmvessel density (MVD)of peritoneum tumor node was calculated by immunohistochemical staining with CD31 antibody.Morphological of tumor cell in abdominal cavity and new vascular in peritoneum tumor node were observed by transmission electron microscope.Results With the increase of concentration of panaxoside-Rg3,expressions of the VEGF level of the ascites and the serum and MVD in peritoneum dropped(P＜0.05)and decreased more than that in the NS group and the DDP group(P＜0.05).Morphological changes of tumor ceHs in panaxoside-Rg3 group were observed with electronic scope,more apoptosis and necrosis cells were found.Capillary vessel basal lamina was smoothing.Condusion Panaxoside-Rg3 decreases the permeability of mierangium and inhibit the neovascula-rization of peritoneum by decreasing the VEGF level,accordingly,panaxoside-Rg3 inhibit the formation of malignant ascites.This would offer foundation of theory for clinical application.
